(RTTNews) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.

Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% 

The average one-year price target for Charles River Laboratories International (NYSE:CRL) (BMV:CRL) has been revised to $307.39 / share, up 11.46% from the prior estimate of $275.80 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and

Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.03%.  December E-mini S&P futures (ESZ26 ) fell -0.10%, and December E-mini...

Stocks Finish Mostly Lower as Bond Yields Soar

The S&P 500 Index ($SPX ) (SPY ) is down by -0.41% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.68%.  December E-mini S&P futures (ESZ26 ) are down -0.48%, and December E-mini...

Stocks Retreat as Bond Yields Climb on Inflation Risks

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Equal Weight ETF (Symbol: RSP) where we have detected an approximate $827.8 million dollar inflow -- that's a 0.8% increase week

Notable ETF Inflow Detected - RSP, ZBRA, CRL, EXPE

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International, Inc. News